As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive. That’s where this secondary analysis comes in. The original Phase 3 trial randomized 611 patients with ATTR-CM to Attruby or placebo. Now, researchers are […] The post Another Look at Attruby Reveals Bolstered Benefits appeared first on Cardiac Wire .